Together these findings suggest that Life Sciences firms, and the R&D organizations within them, are at a crossroads in terms of moving to a patient outcome oriented model. R&D executives clearly want to contribute to improving patient outcomes, and see a place for digital in their organizations for helping accomplish this goal. The difference in investment strategies, however, may mean that the journey to that destination may be far longer for some than others. With just over half of the executives surveyed identifying integration of external patient data and increasing patient input at trials as priorities, there appears to be a difference of opinion as to what is actually needed to be patient outcome focused. While some companies are taking a broader perspective and investing in improving internal and external collaboration, frequently by leveraging digital enablers, others remain wedded to more traditional approaches.